Related Experiment Videos

Drug treatment for chronic systolic heart failure

K Mörike1, J R Sindermann

  • 1Institute of Experimental and Clinical Pharmacology and Toxicology, Department of Clinical Pharmacology, University Hospital Tuebingen, Otfried-Müller-Strasse 45, Tuebingen, Germany. klaus.moerike@med.uni-tuebingen.de

The Thoracic and Cardiovascular Surgeon
|January 27, 2010
PubMed

Insights

Standard heart failure treatment involves angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and beta blockers. Additional medications like aldosterone antagonists or digitalis glycosides may be used, alongside diuretics for symptom management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Chronic systolic heart failure management relies on established drug classes.
  • Prognostic benefits of key medications are supported by extensive clinical evidence.

Purpose of the Study:

  • To outline current pharmacotherapeutic strategies for chronic systolic heart failure.
  • To discuss the role of various drug classes in managing heart failure.

Main Methods:

  • Review of clinical trial data and established treatment guidelines.
  • Analysis of drug efficacy and potential adverse effects in heart failure.

Main Results:

  • Angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin II receptor blockers (ARBs) and beta blockers are foundational treatments.
  • Aldosterone antagonists, digitalis glycosides, and diuretics offer additional benefits or symptomatic relief.
  • Certain medications can exacerbate or precipitate heart failure.

Conclusions:

  • A multi-drug approach is standard for chronic systolic heart failure.
  • Individualized treatment plans are necessary, considering disease stage and patient factors.
  • Awareness of drug-induced heart failure is crucial for patient safety.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...